Showing results (231-240 of 245) with videos related to

Sort By:
Pageof 25
The New England Journal of Medicine|September 27, 2019
Ticagrelor with or without Aspirin in High-Risk Patients after PCIRoxana Mehran, Usman Baber, Samin K Sharma, et al.
Circulation|May 23, 2019
Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary InterventionPhilip Urban, Roxana Mehran, Roisin Colleran, et al.
Lancet (London, England)|September 2, 2017
Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trialRaymond R Townsend, Felix Mahfoud, David E Kandzari, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|December 9, 2021
Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT studyGeorge Dangas, Usman Baber, Samin Sharma, et al.
European Heart Journal|May 23, 2019
Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding RiskPhilip Urban, Roxana Mehran, Roisin Colleran, et al.
Heart (British Cardiac Society)|June 25, 2025
Amphilimus-eluting versus zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: extended follow-up of the SUGAR randomised controlled trialPablo Salinas, Rafael Romaguera, Josep Gómez-Lara, et al.
JACC. Cardiovascular Interventions|February 19, 2021
Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-AnalysisMarco Valgimigli, Roxana Mehran, Anna Franzone, et al.
European Heart Journal|October 21, 2020
Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACSUsman Baber, George Dangas, Dominick Joseph Angiolillo, et al.
European Heart Journal|June 3, 2021
The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF studyEwa A Jankowska, Bridget-Anne Kirwan, Mikhail Kosiborod, et al.
JACC. Cardiovascular Interventions|October 6, 2022
Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass IndexVijay Kunadian, Usman Baber, Carlo A Pivato, et al.
Pageof 25